Clinical trial
A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia
NCT03265717 is registered in ClinicalTrials.gov with Invectys as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia
- Lead sponsor
- Invectys
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 25, 2018
- Completion date
- June 30, 2020
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.